不同剂量奥氮平治疗老年抑郁障碍伴焦虑痛苦患者的疗效<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2024.03.005

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1143 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the efficacy of different doses of olanzapine in treating elderly depression patients with comorbid anxiety and pain, as well as its effects on somatic symptoms and sleep quality. 【Methods】 A total of 120 elderly patients with depression plus comorbid anxiety and pain from our hospital were randomly divided into a low-dose group and a high-dose group, with 60 patients in each group. Both groups were treated with paroxetine, while patients in the control group received a high dose of olanzapine(10 mg/dose) and in the observation group received a low dose of olanzapine(2.5 mg/dose), both for three months. The effectiveness and adverse reactions of the two groups were compared. The scores on the Hamilton Depression Scale(HAMD), Hamilton Anxiety Scale(HAMA), Patient Health Questionnaire-15(PHQ-15) for the severity of somatic symptoms, Pittsburgh Sleep Quality Index(PSQI), and levels of fasting blood glucose(FBG), total cholesterol(TC) and triglycerides(TG) were compared before and after treatment in both groups.【Results】 There was no significant statistical difference in the overall effectiveness rate between the two groups(P>0.05). There were no significant statistical differences in the HAMD, HAMA, and PHQ-15 scores between the two groups either before or after treatment(P>0.05), while there was a significant reduction in the scores after treatment if compared to before treatment in each group(P<0.05). There were no significant statistical differences in the individual and total PSQI scores between the two groups before and after treatment(P>0.05), however, the scores of both groups after treatment were significantly lower than those before treatment(P<0.05). There were no significant statistical differences in levels of FBG, TC and TG between the two groups before treatment(P>0.05). After treatment, the FBG, TC, and TG levels in the high-dose group were significantly higher than those before treatment, while the FBG,TC and TG levels of the high-dose group were significantly higher than those of the low-dose group(P<0.05). The total incidence of adverse reactions in the low-dose group was significantly lower than that in the high-dose group(P<0.05).【Conclusion】 Olanzapine can improve depression, anxiety, somatic symptoms, and sleep quality in elderly patients with depressive disorder plus comorbid anxiety and pain. Using a low dose of olanzapine can reduce the risk of hyperglycemia and hyperlipidemia, and it has fewer adverse reactions.

Key words： Olanzapine/AD Depression/CO Anxiety/CO Aged Treatment Outcome

Received: 02 April 2023

PACS:

R749.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TAO Tao
	ZHANG Boyu
	ZHENG Shuang
	et al

Cite this article:

TAO Tao,ZHANG Boyu,ZHENG Shuang, et al. Efficacy of Different Doses of Olanzapine in Treating Elderly Patients with Depressive Disorders Accompanied by Anxiety and Pain[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 336-339.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.03.005 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I3/336

[1] WU G L,LI T Y . Focus on effects of chinese medicine on improving anxiety-depression and quality of life of patients with primary sjgren's syndrome[J].Chin J Integr Med,2020, 26(7):486-489.
[2] KIM H,RICHARDSON D,SOLBERG S V . Understanding somatic symptoms associated with south Korean adolescent suicidal ideation, depression, and social anxiety[J].Behavioral Sci,2021, 11(11):151.
[3] CURROW D C,CHANG S,REDDEL H K,et al. Breathlessness, anxiety, depression, and function the BAD-F Study: A cross-sectional and population prevalence study in adults[J].J Pain Symptom Manage,2020, 59(2):197-205.
[4] MAFFIOLETTI E,VALSECCHI P,MINELLI A,et al. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients[J].Drug Dev Res,2020, 81(6):754-761.
[5] 美国精神医学学会.精神障碍诊断与统计手册[M].张道龙,译.5版.北京:北京大学出版社,2014:77-89.
[6] 高庆, 李志雄, 杨亚黎,等. SSRIs联合不同剂量坦度螺酮治疗伴有焦虑抑郁症的疗效和安全性[J].重庆医学, 2018, 47(32):4126-4129.
[7] 张俊青, 张增, 蔡文文. 米那普仑与度洛西汀治疗抑郁症的疗效和安全性评价[J].中国医院药学杂志, 2019, 39(21):2172-2175.
[8] 李红娟, 王璇, 徐海婷,等. 正念冥想训练联合心理引导治疗对中重度抑郁症患者情绪加工和认知控制的影响[J].国际精神病学杂志, 2019, 46(3):470-473.
[9] 钱洁, 任致群, 于德华,等. 患者健康问卷躯体症状群量表在综合医院的筛检价值[J].中国心理卫生杂志, 2014, 28(3):173-178.
[10] YU J,RAWTAER I,FENG L,et al. The functional and structural connectomes associated with geriatric depression and anxiety symptoms in mild cognitive impairment: Cross-syndrome overlap and generalization[J].Prog Neuro-psychopharmacol Biol Psychiatry,2021, 110(12):110329.
[11] LUAN S,WAN H,WANG S,et al. Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials[J].Neuropsychiatr Dis Treat,2017, 13(1):609-620.
[12] 王天道, 潘明, 刘向来,等. 奥氮平治疗精神分裂症患者MC4R rs489693基因多态性与糖脂代谢紊乱关联性分析[J].海南医学院学报, 2020, 26(17):1328-1330.
[13] 张强, 王明洪, 谢镇延. 帕罗西汀联合奥氮平治疗精神分裂症伴抑郁的疗效观察[J].实用临床医药杂志, 2017, 21(24):96-97.
[14] 朱羞阳, 陈晓健, 柴波,等. 帕罗西汀联合低剂量奥氮平治疗围绝经期抑郁的临床研究[J].空军医学杂志, 2020, 36(5):433-436.
[15] 付金芳. 奥氮平联合草酸艾司西酞普兰片对抑郁症患者睡眠质量及抑郁程度的影响[J].中国药物与临床, 2019, 19(9):1466-1468.
[16] 张付全, 王军, 王国强. 低剂量奥氮平抗抑郁增效作用及对自主神经功能影响的对照研究[J].临床精神医学杂志, 2017, 27(1):41-43.
[17] 林春燕, 周红蕊, 黎顺成,等. 探讨奥氮平对首发精神分裂症伴肥胖患者认知功能、糖脂代谢及相关激素指标水平的影响[J].中国医院药学杂志, 2019, 39(9):954-958.